Encore Dermatology to Acquire US Commercialization Rights for Dr. Reddy's Three Dermatology Products
Shots:
- Encore through its subsidiary Promius Pharma- has acquired US commercialization rights for Sernivo spray (betamethasone dipropionate)- Trianex (Triamcinolone Acetonide Ointment- USP) and Promiseb from Dr. Reddy
- The focus of the acquisition is to expand Encore’s portfolio of dermatology products for the treatment of skin diseases such as psoriasis- atopic dermatitis and acne
- Sernivo (betamethasone dipropionate) spray 0.05% is targeted to reduce the symptoms of mild-to-moderate plaque psoriasis- such as itching- flaking & redness. Trianex 0.005% is a corticosteroid ointment used to relief inflammatory and itching symptoms of corticosteroid-responsive skin diseases
Ref: Business Wire | Image: Twitter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com